Therefore, the above findings imply that GRP78 down-regulation is suitable to serve as a supplementary strategy to improve the HCC prevention efficacy of current antiviral options once the enhancements of HBV replication and HBeAg secretion are effectively blocked. This evidence concerns the gene HSPA5 and hepatocellular carcinoma.